Literature DB >> 7537626

Serum CD44 splice variants in cervical cancer patients.

C Kainz1, C Tempfer, S Winkler, G Sliutz, H Koelbl, A Reinthaller.   

Abstract

Aberrant expression of the cell adhesion molecule CD44 has been detected in human tumours and has been shown to be associated with metastasis and poor prognosis in human malignancies. We evaluated serum levels of different soluble CD44 molecules (CD44 standard form and CD44 splice variants v5 and v6) in cervical cancer patients stage IB to IIIB. Two-hundred three serum samples were analysed. Serum levels of CD44st and CD44v5 showed no significant correlation with the presence or absence of cervical cancer. The splice variant CD44v6 showed a mean concentration of 227.3 +/- 90.9 (minimum 71.4, maximum 543.9) ng/ml when tumour was present and a mean concentration of 198.7 +/- 135.4 (minimum 67.2, maximum 696.3) ng/ml in cases of complete remission (P-value = 0.0001). However, in this preliminary study the sensitivity/specificity characteristic of CD44v6 was poor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537626     DOI: 10.1016/0304-3835(95)03708-5

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

1.  Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis.

Authors:  Zahra Amirghofran; Seyed Amir Jalali; Seyed Vahid Hosseini; Mohammad Vasei; Behnam Sabayan; Abbas Ghaderi
Journal:  J Gastrointest Cancer       Date:  2009-03-31

2.  Serological evaluation of soluble CD44 in renal cancer.

Authors:  M Kan; H Kanayama; S Naruo; M Tsuji; K Kojima; Y Kurokawa; S Kagawa
Journal:  Jpn J Cancer Res       Date:  1996-11

3.  Label-free fiber-optic spherical tip biosensor to enable picomolar-level detection of CD44 protein.

Authors:  Aliya Bekmurzayeva; Zhannat Ashikbayeva; Zhuldyz Myrkhiyeva; Aigerim Nugmanova; Madina Shaimerdenova; Takhmina Ayupova; Daniele Tosi
Journal:  Sci Rep       Date:  2021-10-01       Impact factor: 4.379

4.  Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer.

Authors:  G Sliutz; C Tempfer; S Winkler; P Kohlberger; A Reinthaller; C Kainz
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.